Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform

Stock Information for Lexaria Bioscience Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lexaria Bioscience Corp.

Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
Lexaria Preparing For Strategic Growth
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.